Plain-English translation of NCT07637877 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding rilpivirine to your current HIV medications can help your immune system recover more fully. Some people with HIV have their virus controlled for years with treatment, but their immune system still doesn't bounce back the way doctors hope. This study explores whether this additional medication might trigger the death of hidden HIV-infected cells and help restore immune function.
Even when HIV medications keep the virus undetectable, some people experience incomplete immune recovery — meaning their CD4 count (a key marker of immune strength) stays low despite years of successful treatment. This medication may work differently than standard antiretroviral drugs, potentially addressing the persistent hidden reservoir of HIV that keeps the immune system suppressed.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to continue your current HIV medications alone, or to add this medication to your regimen. The study involves visits to the clinic where your CD4 count, viral load, and immune function will be monitored. You'll need to commit to continuing your current HIV medications unchanged throughout the study period while researchers track whether the additional medication helps restore your immune system.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China